Clinical performance of fluticasone propionate nasal drops

The efficacy and safety of fluticasone propionate (FP) nasal drops were inv estigated in two multicentre, randomized, placebo-controlled trials. Patien ts received FP 400 mu g once or twice daily for 12 weeks and then FP 400 mu g once daily for a further 12 weeks. FP 400 mu g significantly reduced pol yp size and improved peak nasal inspiratory flow, rhinitis symptoms and sen se of smell when administered twice daily. Significant reductions in polyp size were not achieved with once daily administration, but clinical benefit s were observed for peak nasal inspiratory flow. Both dosing regimens were well tolerated, with an overall incidence of adverse events which was simil ar to placebo.